评估阿尔茨海默病试验中的临床进展措施：系统回顾与荟萃分析

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2024-10-22 DOI:10.1002/alz.14314

Jonathan McLaughlin, William J. Scotton, Natalie S. Ryan, John A. Hardy, Maryam Shoai

{"title":"评估阿尔茨海默病试验中的临床进展措施：系统回顾与荟萃分析","authors":"Jonathan McLaughlin, William J. Scotton, Natalie S. Ryan, John A. Hardy, Maryam Shoai","doi":"10.1002/alz.14314","DOIUrl":null,"url":null,"abstract":"Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"17 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis\",\"authors\":\"Jonathan McLaughlin, William J. Scotton, Natalie S. Ryan, John A. Hardy, Maryam Shoai\",\"doi\":\"10.1002/alz.14314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/alz.14314\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14314","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

评估阿尔茨海默病（AD）的治疗方法有赖于可靠的AD进展测量工具。在这项分析中，我们评估了在随机对照试验（RCT）中，淀粉样蛋白（Aβ+）阳性状态在入组前已被证实的阿尔茨海默病临床进展测量的敏感性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis

Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.